Keros Therapeutics (NASDAQ:KROS) Sees Large Volume Increase – Here’s Why

Keros Therapeutics, Inc. (NASDAQ:KROS) shares saw unusually-strong trading volume on Friday . Approximately 923,607 shares traded hands during mid-day trading, an increase of 110% from the previous session’s volume of 439,983 shares.The stock last traded at $19.67 and had previously closed at $18.43.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on KROS shares. Scotiabank dropped their price target on Keros Therapeutics from $77.00 to $44.00 and set a “sector outperform” rating on the stock in a research note on Friday. William Blair downgraded shares of Keros Therapeutics from an “outperform” rating to a “market perform” rating in a research report on Thursday. HC Wainwright decreased their price target on shares of Keros Therapeutics from $100.00 to $47.00 and set a “buy” rating for the company in a report on Friday. Jefferies Financial Group started coverage on shares of Keros Therapeutics in a research note on Tuesday, November 5th. They set a “buy” rating for the company. Finally, Bank of America cut their target price on Keros Therapeutics from $81.00 to $76.00 and set a “buy” rating on the stock in a research report on Thursday, September 12th. Three investment analysts have rated the stock with a hold rating and eleven have issued a buy rating to the stock. According to MarketBeat, Keros Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $85.67.

Keros Therapeutics Stock Performance

The firm has a market cap of $762.75 million, a price-to-earnings ratio of -3.61 and a beta of 1.20. The business’s 50 day moving average price is $59.11 and its 200 day moving average price is $52.65.

Keros Therapeutics (NASDAQ:KROS) last released its quarterly earnings results on Wednesday, November 6th. The company reported ($1.41) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.28) by ($0.13). Keros Therapeutics had a negative return on equity of 41.74% and a negative net margin of 27,890.94%. The business had revenue of $0.39 million during the quarter. During the same period last year, the firm earned ($1.33) earnings per share. The company’s revenue for the quarter was up 4750.0% compared to the same quarter last year. Sell-side analysts anticipate that Keros Therapeutics, Inc. will post -5.26 earnings per share for the current fiscal year.

Institutional Trading of Keros Therapeutics

Institutional investors have recently modified their holdings of the stock. KBC Group NV boosted its stake in shares of Keros Therapeutics by 52.0% in the third quarter. KBC Group NV now owns 1,263 shares of the company’s stock worth $73,000 after acquiring an additional 432 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. grew its holdings in Keros Therapeutics by 26.0% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,357 shares of the company’s stock valued at $77,000 after buying an additional 280 shares in the last quarter. Values First Advisors Inc. purchased a new stake in shares of Keros Therapeutics in the third quarter valued at about $89,000. Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of Keros Therapeutics during the 2nd quarter worth approximately $128,000. Finally, LMR Partners LLP purchased a new position in Keros Therapeutics in the third quarter worth approximately $213,000. Institutional investors and hedge funds own 71.56% of the company’s stock.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.